CAMBRIDGE, Mass., Aug. 26, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its executives will participate in two investor conferences in September: Wells Fargo Healthcare Conference on September 4-6, 2024 in Boston and H.C. Wainwright 26th Annual Global Investment Conference on September 9-11, 2024 in New York.
Wells Fargo Healthcare Conference
John Butler, Chief Executive Officer, will present on Friday, September 6 at 9:30 a.m. EST.
H.C. Wainwright Global Investment Conference
Mr. Butler will participate in a fireside chat on Monday, September 9 at 10:30 a.m. EST.
A webcast of each presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com following the conferences. A replay of the webcast will also be available for approximately 90 days following the conference through the Investors section of Akebia's website at https://ir.akebia.com.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.35 |
| Daily Change: | -0.02 -1.46 |
| Daily Volume: | 1,420,855 |
| Market Cap: | US$283.890M |
September 05, 2024 August 08, 2024 June 27, 2024 June 24, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
